LBS Healthcare Conference 2023
Speakers
Day 1- 29th March 2023

Dame Barbara Hakin
Health Advisory Consultant and former National Director NHS
Dame Barbara has a unique blend of clinical and managerial experience in the NHS, twenty years as a doctor and twenty in management at the most senior level. She was widely known and respected as an experienced system leader.
Having been both a PCT and SHA Chief Executive, she was latterly Deputy Chief Executive and Chief Operating Officer of NHS England, responsible for overseeing all national performance – oversight of CCGs through the regional teams as well as specialised commissioning and all primary care commissioning and contracting. She was recognised as one of the most influential individuals in the NHS, working closely with Ministers and key decision makers for almost two decades.
In her early career she spent twenty years as a General Practitioner, moving on to be the Clinical Chair of Bradford PCG then Chief Executive of the PCT. During this time she was instrumental in many initiatives which transformed the way care was delivered. Many of these initiatives had an influence on national policy.
Since her retirement from the NHS she provides strategic advice to a number of UK and international commercial companies who provide services to the health and care system. She has championed the cause of the full range of expertise the independent sector can bring, including the direct provision of care and the use of data and analytics as well as supporting innovations and new technologies into the market.
Panel | Innovation and Venture Capital
29th March 5:30pm-6:30pm BST

Dr. Marek Tyl (Moderator)
Scientific Advisor, Innovation Hub Lead
Takeda
Dr. Marek Tyl
Dr Marek Tyl is currently a Scientific Advisor and a Lead of the Innovation Hub at Takeda UK. Previously, he founded the Innovation Forum a global accelerator and network of innovative companies, entrepreneurs, investors, researchers and policy makers (10,000 individual members) with branches in Europe, Asia and North America. Marek also founded Cambridge Squared, a boutique consultancy focusing on sourcing and due diligence of investment opportunities (therapeutics and medical devices) for leading multinational pharma clients. Marek’s background is in molecular biology and biochemistry with a PhD from Cambridge University followed by a Post Doc at Imperial College London.

Georgina Askeland
Senior Investment Associate
Hadean Ventures
Georgina Askeland
Georgina joined Hadean as an Investment Analyst in 2020. She has an academic background in molecular biology, from University College London (UCL) and University of Oslo.
Her PhD focussed on mitochondria, DNA repair and Huntington’s Disease. She was involved in characterising a novel minipig model for Huntington’s Disease, discovered a possible blood biomarker for the disease in patients, and published her results in several scientific articles.
Outside academia, Georgina has worked in scientific publishing in London where she commissioned, peer reviewed and published many scientific articles. She has also worked for the UK Medical Research Council as a science writer.
More recently she worked as an innovation consultant, where she helped health start-ups develop their R&D projects and secured more than €1m in non-dilutive funding through successful grant proposals.
In 2021, Georgina completed her MBA from Quantic School of Business and Technology.

Jack O’Meara
CEO
Ochre Bio
Jack O'Meara
Jack O’Meara is co-founder and CEO of Ochre Bio. Ochre Bio is developing a portfolio of therapies for chronic liver and cardiometabolic diseases, by combining advances in genomics, RNA medicine and organ perfusion. Jack received his Bachelor’s degree in Biomedical Engineering from National University of Ireland, Galway and his Masters from the University of Notre Dame.

Michaël Niddam
Co-Founder and CEO
Kamet Ventures
Michaël Niddam
Michaël Niddam is the CEO and Co-Founder of Kamet Ventures. Prior to Kamet, Michaël was a Partner in the Insurance and TMT practices of Boston Consulting Group (BCG). During his time at BCG, Michaël was instrumental in developing BCG’s offering in the digital space and was also involved in the opening of the firm’s offices in Israel. Michaël has also launched three successful technology start-ups focused on media and Big Data. He is a graduate of École Polytechnique and ENSAE.

Dr. Anushka Patchava
Deputy Chief Medical Officer at Vitality
Anushka has over 10+ years clinical and corporate experience, devising and implementing tactical, data-driven and technology-enabled strategies to drive profitability and growth, across pharmaceutical, digital health, medical device and health insurance sectors. She has practiced as a physician in the UK and US, and has lived and/or worked in Europe, Middle East, America and the Asia-Pacific markets. In her current role as Deputy Chief Medical Officer at Vitality, Anushka is focused on managing clinical risk and delivering high quality care through innovative clinical pathways to drive robust health outcomes. Outside of the day-job, Anushka serves as an Expert Advisor to the United Nations (CEFACT) in Artificial Intelligence and Blockchain and can often be found training for the next regional power-lifting competition or obstacle course endurance race.
Panel | The Inflation Reduction Act's Impact on Pharma
29th March 7:30pm-8:15pm BST

Prof. Nicos Savva (Moderator)
Professor of Management Science and Operations, London Business School
Prof. Nicos Savva
Professor Savva’s current research focuses on hospital operations and healthcare management. His research has appeared in leading journals such as Management Science, M&SOM, Production & Operations Management, and Nature Biotechnology. He is an Associate Editor of Management Science, M&SOM and senior editor of Production & Operations Management. He holds an honorary appointment at Guy’s and St Thomas’ NHS Foundation trust, a large hospital system based in London, and has acted as a consultant to hospitals, biotech companies, high-tech start-ups, retail firms and a hedge fund. He has also taught at The Wharton School, Columbia GSB, and at Judge Business School, University of Cambridge.
He holds a PhD in Management Science, an MPhil in Finance (Financial Engineering) and a BA in Physics, all from the University of Cambridge.

Stephen Sutherland
Managing Director & Partner
BCG
Stephen Sutherland
Stephen Sutherland is Managing Director & Partner at BCG London, working within the Healthcare space. In particular, Stephen spends most of his time working with payer and provider organisations including the NHS. At BCG, his experiences include strategy, large-scale change and transformation, clinical reconfiguration, and organisational development and design.
Outside of BCG, Stephen has worked as a Director of Service Improvement in an NHS Acute Hospital, and as Head of Strategy in Local Government.

Antonio Iervolino
Partner
Putnam Associates
Antonio Iervolino
Antonio leads the Commercial European team at Putnam, advising biopharmaceutical companies across a range of strategy and transformation topics, from launch and organizational strategy, change management to portfolio development and optimization. He has partnered with clients across a wide range of therapy areas and led transformation programs at both HQ and affiliate level.
Prior to joining Putnam, Antonio was in senior roles at IQVIA and Mundipharma (pricing and access, commercial operations). At IQVIA, he led the EMEA Brand and Commercial Strategy practice as well as global consulting in the Nordics, UK, Ireland and BENELUX. He has a background in business management and economics and executive education in R&D strategy (INSEAD) and Innovation (MIT).

A/Prof. Aris Angelis
Associate Professor of Health Economics LSHTM
A/Prof. Aris Angelis
Dr Aris Angelis is an Assistant Professor in Health Economics with the Department of Health Services Research and Policy at the London School of Hygiene and Tropical Medicine (LSHTM). Before joining LSHTM, Aris was at the London School of Economics and Political Science (LSE), with the Department of Health Policy, where he is now a Visiting Fellow. He was a 2021-2022 National Institute for Health and Care Excellence (NICE) Scholar, working on the appraisal of the Cancer Drugs Fund for advancing value assessment methods of new cancer drugs. In the past, Aris has undertaken contracted research, training and advisory work for the Department of Health and Social Care, the European Commission, the World Health Organization, national health ministries and various biopharmaceutical organisations.
More info can be found on my LSHTM profile:
Day 2- 30th March 2023

Amy Landucci
Chief Technology and Digital Officer at Haleon
Amy is Haleon’s Chief Digital and Technology Officer, a role she’s held since 2021, while the business was still part of GSK.
Prior to joining GSK in 2017, as Chief Information Officer for Consumer Healthcare, Amy spent more than a decade at Novartis, where she was most recently the Global Head of Digital Medicines. She was responsible for defining and delivering the “beyond the pill” strategy and solutions to accelerate Novartis’s entrance into Digital Medicines. Prior to this role, Amy was Chief Information Officer for the Novartis OTC Division.
Amy previously served on the Board of Directors for Healthy Women, the leading independent, non-profit health information source for women in the US with a mission to educate and empower women to make informed health choices for themselves and their families.

David Pyott | Pursuing innovation in the healthcare and pharmaceutical markets
Incoming Governing Body Chair for London Business School, Board Member of Philips, Alnylam Pharmaceuticals, BioMarin Pharmaceutical and Former Chairman and CEO at Allergan
Dr. David Pyott is an accomplished international pharmaceutical executive with more than 30 years of leadership and management experience with particular expertise in organizational scaling.
Most recently, he served as Chairman and Chief Executive Officer of Allergan, Inc. where, over 17 years in this role, he transformed the company from a small eye care business with $1 billion in annual sales into a global specialty pharmaceutical and medical device company with 2014 annual sales of over $7 billion and more than 10,000 employees. Before that, he served as Head of the Novartis Nutrition Division and served as a member of the Executive Committee of Novartis AG.
In addition to Pliant, David currently serves as a member of the Board of Directors of Alnylam Pharmaceuticals and BioMarin Pharmaceutical and is a member of the Supervisory Board of Royal Philips in the Netherlands, a public diversified health technology company. David will also be the Governing Body Chair of London Business School from 1 May 2023.
David also serves as Deputy Chairman of the Governing Board of the London Business School, President of the Ophthalmology Foundation, President of the Advisory Board of the American Academy of Ophthalmology and is a member of the Executive Committee and Trustee of the California Institute of Technology.
David holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School.
Panel | BigTech and Healthcare
30th March 7:30pm-8:15pm BST

Prof. Kamalini Ramdas- Moderator
Professor of Management Science and Operations, London Business School
Prof. Kamalini Ramdas
Professor Kamalini Ramdas is an expert in the innovation arena. Her current research examines new ways to create value through innovation, including: service innovation, operational innovation and business model innovation. She has also examined the amount of product variety and component-level variety that firms should offer, and how variety can be managed effectively through design.

Kira Levy
Head of Healthcare UK
Amazon Web Services
Kira Levy
Kira is an experienced health care leader, with over twenty years experience working for public and private health systems across the globe. She is currently the head of healthcare UK at Amazon Web Services (AWS). I have extensive experience working in healthcare strategy and across the product lifecycle, from initial market analysis and ideation to product delivery and evaluation.

Dr. Vishaal Virani
Head of UK Health
YouTube
Dr. Vishaal Virani
Vishaal started his career as an NHS doctor, and subsequently transitioned into healthcare strategy consulting. He worked in strategy consulting for four years, with a particular focus on due diligence for private equity firms, and corporate strategy for hospitals and medical technology companies.
He then chose to pursue a longstanding interest in leveraging digital health to meaningfully improve patient outcomes – initially as business development and client success lead at Ada Health, a venture-backed AI health technology company; and then managing digital health solutions for a FTSE 100 consumer healthcare company that owns global brands such as Durex, Nurofen and Dettol. Vishaal now works at YouTube, where he is building out the brand new Health offering to empower millions of YouTube users and NHS organisations across the UK.
Vishaal is also a co-founder of Doctorpreneurs, the world’s largest community of medical innovators, governor of the Royal Free NHS Trust, guest lecturer on digital health, contributor to NHS innovation organisations, and mentor to various health tech startups. He has also previously served as a board member at the Youth Hostels Association and as a primary school governor.

Julius Neiser
BCG X.Ventures Managing Director and Partner
Julius Neiser
Julius is a BCG X.Ventures Managing Director & Partner in London. He is a core member of BCG London’s Healthcare practice, with a focus on health tech ventures. He works mainly with pharmaceutical companies and health systems to build new digital health solutions. He also leads the BCG Health Tech Hub, working with innovators to radically improve health outcomes through technology.

Ilya Yuffa
Executive Vice President and President, Lilly International
With a tenure of more than 25 years at Lilly, Ilya most recently served as senior vice president of Lilly Bio-Medicines and previously vice president of U.S. Diabetes for Lilly USA from 2018 to 2020.
Since joining Lilly in 1996 as a financial analyst, Ilya has held a number of positions in finance, business development, sales and general management. He served as managing director of the Israeli affiliate from 2008 until 2011, senior sales director of osteoporosis from 2011 until 2013, and held senior leadership positions within six sigma and ethics and compliance from 2013 until 2017. In 2017, Ilya was named president and general manager of Lilly’s Italy Hub, leading the commercialization of the entire Lilly portfolio in more than 25 countries.
Born in St. Petersburg, Russia, Ilya grew up in Colorado. His career has taken him around the world, and he has lived and worked in the United Kingdom, Czech Republic, Italy and Israel.
Ilya earned a Bachelor of Science degree from Tulane University in 1996, and a Master of Business Administration degree from the London Business School in 2002.
Ilya is a member of the Board of Directors for the U.S.-Japan Business Council and the Advisory Board of the U.S. Chamber of Commerce China Center. He also serves as a board member for the European Federation of Pharmaceutical Industries and the management committee of Business Equity for Indy.